title: Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin.
abstract: Eradication of H. pylori in patients allergic to penicillin should be performed using regimens without penicillin derivatives. We treated a total of 28 patients allergic to penicillin with a proton pump inhibitor (PPI), metronidazole (250 mg bid) and sitafloxacin (100 mg bid) for one to two weeks. At four to eight weeks after the treatment, the patients underwent the [(13)C]-urea breath test. The overall eradication rate was 100.0%. Mild adverse events were observed. Triple therapy with a PPI, metronidazole and sitafloxacin is well tolerated and effective for the eradication of H. pylori in patients allergic to penicillin.
authors.affiliation: Center for Clinical Research, Hamamatsu University School of Medicine, Japan.
authors.forename: Takahisa
authors.initials: T
authors.lastname: Furuta
authors.forename: Mitsushige
authors.initials: M
authors.lastname: Sugimoto
authors.forename: Mihoko
authors.initials: M
authors.lastname: Yamade
authors.forename: Takahiro
authors.initials: T
authors.lastname: Uotani
authors.forename: Shu
authors.initials: S
authors.lastname: Sahara
authors.forename: Hitomi
authors.initials: H
authors.lastname: Ichikawa
authors.forename: Takuma
authors.initials: T
authors.lastname: Kagami
authors.forename: Takanori
authors.initials: T
authors.lastname: Yamada
authors.forename: Satoshi
authors.initials: S
authors.lastname: Osawa
authors.forename: Ken
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Watanabe
authors.forename: Kazuo
authors.initials: K
authors.lastname: Umemura
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001944:Breath Tests; D065731:Cytochrome P-450 CYP2C19 / Q000378:metabolism; D004334:Drug Administration Schedule; D004342:Drug Hypersensitivity; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage*; D005838:Genotype; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008795:Metronidazole / Q000008:administration & dosage*; D008875:Middle Aged; D010406:Penicillins / Q000276:immunology; D054328:Proton Pump Inhibitors / Q000008:administration & dosage*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D010406:Penicillins; D054328:Proton Pump Inhibitors; D008795:Metronidazole; C076246:sitafloxacin; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19